Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, ...
Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Acquisition extends Resonant's European footprint and adds specialized calibration expertise, IOR/EOR reach, and partner ...
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software.
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...
Marks the Completion of NanoACTIV Integration Across the Company’s Entire Additively Manufactured and Wrought Titanium Spinal ...
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results